



Beacon Discovery is a newly launched, privately held, fully integrated drug discovery incubator. Beacon has broad, deep, multi-disciplinary capabilities with specialized expertise in GPCR research.

Our Value

We leverage recent scientific advances in GPCR biology to more effectively drive drug discovery

Our Assets

- 250K small molecule chemical library
- Database comprising ~20 years of data with small molecule GPCR modulators
- State of the art fully integrated molecular & pharmacology laboratories
- *In vivo* Pharmacology facility

Our Platforms

- Multiple GPCR directed & HTS assay systems
- Biased GPCR ligand, allosteric & persistent signaling approaches

Our Ongoing Research Areas

- Multiple novel CNS targets
- Unique pathway-directed discovery approaches applicable to fibrosis, liver diseases, and others

Our Strategy

- We focus from concept to clinic
- We work with partners to enable clinical investigation of our drug candidates
- We will seek new collaborations in discovery to help our partners move faster into development

An Experienced Drug Discovery Team

- 121 Combined years in drug discovery
- 20+ Compounds into clinical testing
- 300+ Peer reviewed publications
- ~100 Unique patents
- 50+ Invited presentations at scientific meetings
- 40+ Indications
- 20+ Assay platforms
- 150+ Chemical series
- 50+ Targets evaluated

Beacon's Founders

Dominic P. Behan
President & CEO

Carleton Sage
Computational Sciences

Graeme Semple
Chemistry

David Unett
Receptor Pharmacology

Andrew Grottick
CNS Drug Discovery

Sunny Al-Shamma
Biology

Contact

www.beacondiscovery.com

info@beacondiscovery.com

Tel: 858-247-0009